Literature DB >> 35696627

Extraction of Treatment Information From Electronic Health Records and Evaluation of Testosterone Recovery in Patients With Prostate Cancer.

Sunny Guin1, Tomi Jun1, Vaibhav G Patel2, Kristin L Ayers1, Matthew Deitz1, Yuqin Cai1, Xiang Zhou1, Che-Kai Tsao2, William K Oh1, Rong Chen1, Bobby C Liaw2.   

Abstract

PURPOSE: Data quality and standardization remain a challenge when analyzing real-world clinical data. We built a clinical research database, using machine learning and natural learning processing, and investigated factors influencing testosterone recovery (T-recovery) in patients with localized prostate cancer (LPC) after initial androgen deprivation therapy (ADT).
METHODS: Medication and treatment-associated dates missing in structured tables were extracted from patient notes using ConceptMapper, an automated data extraction tool, standardized and curated in Sema4 clinical research database. ADT usage duration was evaluated, and T-recovery in patients with LPC was analyzed by the Kaplan-Meier method and multivariable Cox proportional hazards models. We assessed the prognostic value of post-ADT T-recovery with prostate-specific antigen progression-free survival and failure-free survival.
RESULTS: In total, 4,125 of 30,832 (13.4%) patients with prostate cancer had medication exclusively from notes with high precision and recall, F1 score ≥ 0.95. Association of dates with medication usage had a F1 score of 0.76. ADT duration estimation had higher accuracy combining information from notes to tables from electronic medical record (70% v 45%). Baseline testosterone was the strongest predictor of T-recovery in these patients. Patients with a baseline testosterone ≥ 300 ng/dL recovered in 9.79 versus 38 months for patients with baseline testosterone < 300 ng/dL (P < .0001). Shorter prostate-specific antigen progression-free interval was observed for patients with T-recovery (≥ 300 ng/dL) at 6 months after ADT cessation compared with patients without T-recovery (< 300 ng/dL; 13.7 v 25.1 months; P = .055).
CONCLUSION: We augmented structured electronic medical record data with data extracted from notes and improved the accuracy of medication information for patients. ADT exposure and T-recovery in patients with LPC produced results consistent with the literature and clinical experience and illustrates the power of applying machine learning methods to enhance the quality of real-world evidence in answering clinically relevant questions.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35696627      PMCID: PMC9225507          DOI: 10.1200/CCI.22.00010

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  14 in total

Review 1.  Localized Prostate Cancer: Treatment Options.

Authors:  Stephen Brawley; Ravinder Mohan; Christopher D Nein
Journal:  Am Fam Physician       Date:  2018-06-15       Impact factor: 3.292

Review 2.  Androgen deprivation therapy: evidence-based management of side effects.

Authors:  Hamed Ahmadi; Siamak Daneshmand
Journal:  BJU Int       Date:  2013-01-25       Impact factor: 5.588

3.  Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.

Authors:  U W Tunn; G Canepa; A Kochanowsky; E Kienle
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-09       Impact factor: 5.554

4.  Trie-based rule processing for clinical NLP: A use-case study of n-trie, making the ConText algorithm more efficient and scalable.

Authors:  Jianlin Shi; John F Hurdle
Journal:  J Biomed Inform       Date:  2018-08-06       Impact factor: 6.317

5.  Real-World Evidence in Oncology: Opportunities and Limitations.

Authors:  Massimo Di Maio; Francesco Perrone; Pierfranco Conte
Journal:  Oncologist       Date:  2019-12-24

6.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

7.  Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.

Authors:  Bruno Nascimento; Eduardo P Miranda; Lawrence C Jenkins; Nicole Benfante; Elizabeth A Schofield; John P Mulhall
Journal:  J Sex Med       Date:  2019-05-09       Impact factor: 3.802

8.  Androgen deprivation therapy in the treatment of advanced prostate cancer.

Authors:  Mark A Perlmutter; Herbert Lepor
Journal:  Rev Urol       Date:  2007

9.  Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Authors:  Jun Kawakami; Janet E Cowan; Eric P Elkin; David M Latini; Janeen DuChane; Peter R Carroll
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

10.  Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer.

Authors:  Wook Nam; Se Young Choi; Sang Jun Yoo; Jeman Ryu; Jaehoon Lee; Yoon Soo Kyung; Jae Hyeon Han; Dalsan You; In Gab Jeong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  Investig Clin Urol       Date:  2017-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.